Core Viewpoint - Analysts project that Collegium Pharmaceutical (COLL) will report quarterly earnings of $1.54 per share, a decline of 2.5% year over year, with revenues expected to reach $180.4 million, an increase of 20.5% from the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 2.9%, indicating a reassessment by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics Projections - Analysts estimate 'Total product revenues- Belbuca' at $53.96 million, reflecting a year-over-year increase of 9.4% [5]. - 'Total product revenues- Xtampza ER' is forecasted to reach $49.96 million, indicating a 6.5% year-over-year increase [5]. - The consensus estimate for 'Total product revenues- Symproic' is $3.92 million, showing a decline of 22.9% from the prior-year quarter [5]. - 'Total product revenues- Nucynta' is estimated at $43.52 million, representing a decrease of 10.2% from the year-ago quarter [6]. Stock Performance - Shares of Collegium Pharmaceutical have returned -12% over the past month, compared to a -2.3% change in the Zacks S&P 500 composite [6]. - With a Zacks Rank 3 (Hold), COLL is expected to mirror overall market performance in the near future [6].

Group 1 - Collegium Pharmaceutical, Inc. will report its fourth quarter and full-year 2024 financial results on February 27, 2025, after market close [1] - A live conference call and webcast will follow the financial results release at 4:30 p.m. ET [1] - The conference call can be accessed via specific dial-in numbers for U.S. and international participants [2] Group 2 - Collegium is focused on building a diversified biopharmaceutical company with a strong portfolio in pain management and a recent acquisition in neuropsychiatry [3] - The company aims to grow its commercial portfolio, with Jornay PM identified as the lead growth driver [3] - Collegium is committed to disciplined capital deployment to support its strategic initiatives [3]

Core Viewpoint - Collegium Pharmaceutical, Inc. has appointed Nancy S. Lurker to its Board of Directors, effective February 4, 2025, which is expected to enhance the company's strategic growth and commercial capabilities [1][2]. Company Overview - Collegium Pharmaceutical is focused on building a diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [5]. - The company has a strong portfolio in responsible pain management medications and has recently expanded into the neuropsychiatry market with the acquisition of Jornay PM, a treatment for ADHD [5]. Leadership and Expertise - Nancy S. Lurker brings extensive experience in commercial growth and strategic acquisitions, having previously served as President and CEO of EyePoint Pharmaceuticals and held leadership roles at PDI, Inc. and Novartis Pharmaceuticals [2][3]. - Lurker's appointment is seen as pivotal for Collegium as it enters a new growth phase [2]. Board and Advisory Roles - In addition to her role at Collegium, Lurker serves on the boards of Alkermes plc and Altasciences, LLC, and is involved with advisory boards for Novo Holdings and Stanford Medicine [3]. - Her previous board positions include notable companies such as Cancer Treatment Centers of America and Mallinckrodt Pharmaceuticals [3]. Educational Background - Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville [4].

Core Insights - Collegium Pharmaceutical, Inc. has announced its financial guidance for 2025, projecting product revenues between $735 million and $750 million, with adjusted EBITDA expected to be in the range of $435 million to $450 million, and adjusted operating expenses anticipated between $220 million and $230 million [1][6][4] Financial Guidance for 2025 - The company expects Jornay PM net revenue to exceed $135 million in 2025, driven by its strategic focus on commercial expansion and targeted investments in the product [2][6] - Adjusted EBITDA is projected to be between $435 million and $450 million, while adjusted operating expenses are expected to range from $220 million to $230 million [1][6] Recent Business Highlights - Collegium completed the integration of Ironshore Therapeutics and saw an increase in average weekly prescriptions for Jornay PM during the 2024 back-to-school season [6] - The company repurchased $60 million in shares as part of its $150 million share repurchase program [6] Company Strategy - Collegium aims to build a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a leading portfolio in pain management and a new presence in neuropsychiatry through Jornay PM [5][2] - The company is committed to disciplined capital deployment to create long-term shareholder value while maximizing performance across its entire portfolio [2][5]

Core Insights - The Zacks Rank system focuses on earnings estimates and revisions to identify winning stocks, while also considering trends in value, growth, and momentum [1] - Value investing aims to find undervalued companies through fundamental analysis and traditional valuation metrics [2] Company Analysis: Collegium Pharmaceutical (COLL) - COLL holds a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong interest from investors [3] - The P/S ratio for COLL is 1.69, significantly lower than the industry average of 3.29, suggesting it is undervalued [4] - COLL's P/CF ratio is 5.51, compared to the industry's average of 10.45, indicating a solid cash outlook [5] - Over the past 12 months, COLL's P/CF has fluctuated between 5.26 and 8.61, with a median of 6.44 [5] Company Analysis: Jazz Pharmaceuticals (JAZZ) - JAZZ also has a Zacks Rank of 2 (Buy) and a Value Score of A, making it another attractive option for investors [6] - The forward P/E for JAZZ is 5.87, significantly lower than the industry average of 58.22, and its PEG ratio is 0.84 compared to the industry average of 2.36 [6] - JAZZ's Forward P/E has ranged from 4.97 to 6.87, with a median of 5.62, while its PEG ratio has varied between 0.64 and 1.44, with a median of 1.07 [7] - The P/B ratio for JAZZ is 1.88, slightly above the industry's average of 1.35, with a 52-week range of 1.59 to 2.27 and a median of 1.89 [7] Conclusion - Both COLL and JAZZ exhibit strong value metrics, suggesting they are likely undervalued and present impressive investment opportunities based on their earnings outlook [8]

Investors in Collegium Pharmaceutical, Inc. (COLL) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $20 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Gree ...

Q3'24 Earnings Report ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ November 7, 2024 | Nasdaq: COLL Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to ident ...

Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $1.34 a year ago.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $159.99 million. With the consensus EPS estimate being $1.66, the EPS surprise was -3.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.01%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.56 per share when it actually produced earnings of $1.62, delivering a surprise of 3.85%.Over the ...